Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for lebrikizumab (TBC) for the treatment of adult and adolescent patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Lebrikizumab injection can be used with or without topical corticosteroids.